Pharnext SA represents a commitment to innovation and excellence in the biopharmaceutical industry. With a strong focus on research and development, the company strives to provide groundbreaking solutions to medical challenges. Pharnext prioritizes the improvement of patient lives through its unique business model, which combines conventional pharmaceutical approaches with advanced big data analytics. By leveraging cutting-edge technology and collaboration with industry experts, Pharnext aims to accelerate the discovery and development of new treatments for various diseases. The company's dedication to scientific advancement and a patient-centric approach truly sets Pharnext SA apart in the biopharmaceutical landscape.

Pharnext SA is primarily present in France.

Pharnext SA, a leading pharmaceutical company, has achieved several significant milestones. One notable achievement is the successful completion of its Phase 3 clinical trial for PXT3003, a potential treatment for Charcot-Marie-Tooth disease type 1A (CMT1A). The positive results obtained during this trial have opened doors for Pharnext SA to further advance its development and seek regulatory approval. Moreover, the company has formed strategic collaborations with renowned institutions and industry partners to accelerate research and development efforts. Pharnext SA's commitment to innovation and dedication to addressing critical medical needs reaffirm its position as a prominent player in the pharmaceutical industry.

Pharnext SA is a renowned biopharmaceutical company, specializing in the development and commercialization of innovative drugs. Established in 2007, Pharnext SA has rapidly emerged as a key player in the healthcare industry. Their dedicated team of experts combines cutting-edge science with advanced technologies to create effective treatments for a wide range of diseases. With a strong focus on neurological disorders and orphan diseases, Pharnext SA diligently works toward improving patients' lives and addressing unmet medical needs. Through strategic collaborations and extensive research, the company aims to revolutionize the healthcare landscape by delivering breakthrough therapies and making a lasting impact on global health.

The main competitors of Pharnext SA in the market include pharmaceutical companies such as Novartis, Pfizer, and Sanofi. These companies also operate in the biotechnology sector, focusing on innovation and drug development. With Pharnext SA's expertise in the development of innovative treatments, it competes directly with these industry giants in establishing its presence and gaining market share. Despite the competition, Pharnext SA continues to differentiate itself by leveraging its unique approach to drug discovery and strategic collaborations, enabling it to create value for patients and stakeholders.

Pharnext SA is primarily active in the pharmaceutical industry.

The business model of Pharnext SA is focused on biopharmaceutical research and development. Pharnext conducts innovative research to identify and develop new drug combinations for various medical conditions. By leveraging its proprietary technology platform, Pharnext aims to accelerate the discovery and development of effective treatments. The company collaborates with partners in academia, biotech, and pharmaceutical industries to advance its research programs. With a strong emphasis on precision medicine, Pharnext aims to improve patient outcomes by targeting multiple pathways and addressing complex diseases. Through its holistic approach and extensive expertise, Pharnext strives to deliver high-value therapeutic solutions to improve the lives of patients.

Pharnext P/E suhe on −0,00.

Pharnext KUV on 0,00.

AlleAktien kvaliteediskoor ettevõttele Pharnext on 5/10.

oodatud Pharnext käive on 9,22 mln. EUR.

oodatud Pharnext kasum on −582,38 mld. EUR.

Pharnext SA is a biopharmaceutical company based in France that focuses on developing therapies for the treatment of rare diseases. They use a patented technology platform called Pleotherapy to combine multiple approved drugs and create new treatments with improved safety, efficacy, and duration. Their business activities are divided into research and development, marketing and sales, and clinical development. They aim to provide innovative and effective therapeutic treatments that reduce healthcare costs and benefit patients. Overall, Pharnext's business model is innovative and shows potential for investors and the healthcare sector.

Pharnext maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Pharnext jaoks arvutada või ettevõte ei maksa dividende välja.

Pharnext ISIN on FR0011191287.

Pharnext WKN on A2AM02.

Pharnext tähis on ALPHA.PA.

Viimase 12 kuu jooksul maksis Pharnext dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Pharnext tõenäoliselt dividendi summas 0 EUR.

Pharnext praegune dividenditootlus on .

Pharnext maksab kvartaalset dividendi. See makstakse välja kuudel .

Pharnext maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Pharnext on liigitatud sektorisse 'Tervis'.

Viimase Pharnext dividendide saamiseks 19.9.2024 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 19.9.2024.

Viimane dividendimakse toimus 19.9.2024.

Aastal 2023 maksis Pharnext 0 EUR dividende.

Pharnext dividendid makstakse välja EUR.